BioLineRx Ltd.BLRXEarnings & Financial Report
Nasdaq · biotechnology
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
Revenue
$5.4M
Gross Profit
$4.5M
Operating Profit
$-5.8M
Net Profit
$484.0K
Gross Margin
83.4%
Operating Margin
-107.0%
Net Margin
9.0%
YoY Growth
N/A
EPS
$0.00
Financial Flow
BioLineRx Ltd. Q2 2024 Financial Summary
BioLineRx Ltd. reported revenue of $5.4M for Q2 2024, with a net profit of $484.0K (up 102.6% YoY) (9.0% margin). Cost of goods sold was $897.0K, operating expenses totaled $10.3M.
Key Financial Metrics
| Total Revenue | $5.4M |
|---|---|
| Net Profit | $484.0K |
| Gross Margin | 83.4% |
| Operating Margin | -107.0% |
| Report Period | Q2 2024 |
BioLineRx Ltd. Quarterly Revenue & Net Profit History
BioLineRx Ltd. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 2025 | $304.0K | -94.4% | $-3.9M | -1296.1% |
| Q2 2024 | $5.4M | — | $484.0K | 9.0% |
| Q2 2023 | $0 | — | $-18.5M | N/A |
Income Statement
| Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|
| Revenue | $0 | $5.4M | $304000 |
| YoY Growth | N/A | N/A | -94.4% |
Balance Sheet
| Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|
| Assets | $58.9M | $64.6M | $43.3M |
| Liabilities | $37.9M | $50.6M | $23.2M |
| Equity | $21.1M | $13.9M | $20.1M |
Cash Flow
| Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|
| Operating CF | $-17.7M | $-25.4M | $-2.8M |